Personal Profile

Jing Xu，member of CPC，MD-PhD based in Zhongshan Hospital,specializing in endocrine and metabolic diseases, under the supervision of Prof. Xiaoying Li, director of department of endocrinology of Zhongshan Hospital, Fudan University.

During postgraduate studies: served as correspondent of Party branch of class 2020 in Zhongshan Hospital and head of Party member volunteer based in Shanghai Medical College. 

Research Interests

• Pathogenesis and clinical intervention of diabetes and fatty liver diseases

• Intergenerational inheritance of metabolic diseases

Honors and Awards

• 11 SCI papers and 3 papers in Chinese core journals, including 6 first-author papers and 2 co-authored papers.

• First Class Scholarship of the University (several times)

• Outstanding Student of Fudan University for (twice)

• Outstanding Volunteer of Fudan University Doctoral Medical Corps for three consecutive years (several times)

• Honorary titles such as poster exchange of the 79th Annual Meeting of the American Diabetes Association (ADA)

• Outstanding Award of the Youth Speech Contest of the Endocrine Society Branch of the Shanghai Municipal Medical Association

• Certificate of Excellence of Intellectual Property Specialist of Shanghai Xuhui District, and Certificate of Qualification of GCP Training for Anti-tumor Clinical Trials of the National Cancer Center.

Selected Publications

1. Xu J#, Mao F#, Lu Y, Liu T, Li X*, Li Y*. Hepatic Transcriptomics Reveals Reduced Lipogenesis in High-Salt Diet Mice. Genes. 2023, 14(5):966.

2. Xu J, Yang Y, Ling Y, Lu Z, Gao X, Li X*, Li X. The Association between eGFR and the Aldosterone-to-Renin Ratio and Its Effect on Screening for Primary Aldosteronism. Int J Endocrinol. 2020, 2020:2639813.

3. Xu J, Yang Y, Chen D, Lu Z, Ge J, Li X*, Gao X. Coexistence of Sarcoidosis and Sjögren's syndrome with hypercalcemia and renal involvement: A case report and literature review. Endocr Metab Immune Disord Drug Targets. 2021, 21(4):768-776.

4. Xu J, Mao F*. Role of high-salt diet in non-alcoholic fatty liver disease: a mini-review of the evidence. Eur J Clin Nutr. 2022, 76(8):1053-1059.

5. Zhong P#, Xu J#, Yang D#, Shen Y, Wang L, Feng Y, Du C, Song Y, Wu C, Hu X*, Sun Y*. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduct Target Ther. 2020, 5(1):256.

6. Chen P#, Xu J#, Cui Z#, Wu S, Xie T, Zhang X*. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer. Front. Immunol. 2023, 14:1071675.